실시간
FierceBiotechADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetesClinical OMICsGLP-1 Drugs Lower Risk of Death by 44% in Obesity and Autoimmune DiseaseCellDeep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvationCellReplaying germinal center evolution on a quantified affinity landscapeCellXenophagocytosis blockade enhances interspecies chimerismFierceBiotechADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buyEndpoints News#ADA26: Pfizer monthly shot shows effect on obesity, diabetesEndpoints News#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this yearEndpoints NewsLawmakers propose China restrictions; #ASCO26 recap; and moreFierceBiotech‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEsBrady CorporationLabel Maker Market Forecast Points Higher Toward 2035, Driven by Commercial Micro-Enterprise Demand - IndexBox
eLife 2026년 1월 20일

ATAD2 mediates chromatin-bound histone chaperone turnover

ATAD2 mediates chromatin-bound histone chaperone turnover

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.